# Real-World Outcomes of First-Line Treatment of Metastatic or Locally Advanced Upper Tract Urothelial Carcinoma With Enfortumab Vedotin Plus Pembrolizumab : A French Multicenter Retrospective Observational Study

> **NCT07633353** · — · ENROLLING_BY_INVITATION · sponsor: **Centre Hospitalier Universitaire de Nīmes** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Upper Tract Urothelial Carcinoma

## Interventions

- **DRUG:** enfortumab vedotin plus pembrolizumab in first line setting for advanced upper tract urothelial carcinoma

## Key facts

- **NCT ID:** NCT07633353
- **Lead sponsor:** Centre Hospitalier Universitaire de Nīmes
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-07-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07633353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07633353, "Real-World Outcomes of First-Line Treatment of Metastatic or Locally Advanced Upper Tract Urothelial Carcinoma With Enfortumab Vedotin Plus Pembrolizumab : A French Multicenter Retrospective Observational Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07633353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*